Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events. On January 8, 2026, MoonLake Immunotherapeutics (the “Company”) issued a press release providing an update following the positive feedback recei
. Financial Statements and Exhibits. (d) Exhibits . The following exhibit is being filed herewith: Exhibit Number Exhibit Title or Description 99.1 Press Releas